Halozyme Therapeutics Wins Legal Battle Against Merck Over Keytruda Patent Infringement

Halozyme Secures Legal Victory Against Merck in Patent Dispute

Halozyme Therapeutics, Inc. announces a significant legal development as a German court issues a preliminary injunction against Merck, prohibiting the distribution of the subcutaneous formulation of Keytruda, known as Keytruda SC, within Germany. The Munich Regional Court's ruling is based on findings that Merck's product infringes upon Halozyme's MDASE™ patent (European Patent No. 2 797 622). This injunction effectively halts Merck's launch activities for the subcutaneous version of its cancer immunotherapy, although the intravenous version remains available to patients in Germany. Halozyme's Chief Legal Officer, Mark Snyder, expresses confidence that the injunction will withstand any potential appeals, underscoring the company's dedication to safeguarding its proprietary MDASE technology, which is instrumental in facilitating rapid subcutaneous drug delivery.

The court’s decision is part of a broader legal strategy employed by Halozyme to enforce its MDASE patents against Merck, which has included a lawsuit in the U.S. federal court in New Jersey. In this case, Halozyme alleges that the U.S. marketed version of Keytruda SC, known as QLEX, infringes on 15 of its patents associated with MDASE technology. This technology, rooted in extensive research on nearly 7,000 modifications of human hyaluronidases, is pivotal for enhancing the delivery of therapeutic drugs, providing a competitive edge in the pharmaceutical landscape. Importantly, the enforcement of MDASE patents is distinct from Halozyme's ENHANZE® licensing program, ensuring that this ongoing litigation will not impact the company's revenues derived from ENHANZE® or its collaborations.

Halozyme's commitment to innovation in drug delivery technology is evident as it seeks to enhance patient outcomes and experiences. The company’s focus on protecting its intellectual property not only cements its position in the market but also reflects its broader strategy to leverage its proprietary technology to improve therapeutic options for patients. As the legal proceedings unfold, Halozyme remains positioned to advance its mission of transforming patient care through innovative delivery solutions.

In addition to this legal victory, Halozyme's proactive measures to protect its intellectual property highlight the ongoing competitive dynamics within the biopharmaceutical industry. As companies like Merck pursue advancements in drug formulations, the protection of proprietary technologies becomes crucial for maintaining market positioning and ensuring continued innovation. This legal landscape underscores the importance of robust patent portfolios in fostering an environment of technological advancement while navigating the complexities of drug delivery systems.